Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer
Xinyi Guo(Center for Life Sciences), Yicheng Zhu(Renji Hospital), Xiaohong Zhao(King Center), Na Zhong(Beike Biotechnology (China)), Qinli Sun(King Center), Wenwen Zhang(Takeda (United States)), Lei Zhang(Dalian University of Technology), Ting Zhang(Renji Hospital), Xiaoyuan Chen(Tsinghua University), Wenbo Hu(University of Science and Technology Liaoning), Xinmei Zhang(Southwest Jiaotong University), Ling Ni(King Center), Shichun Lu(Chinese PLA General Hospital), Bowen Xie(University of California, Davis), Hu Nie(BGI Group (China)), Jiesheng Li(BGI Group (China)), Xiaoshuang Wang(Center for Life Sciences), Jing Ge(Renji Hospital)
Cited by 65
Related Papers
Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing
|Nature Medicine|2018|1.8k
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion
|Nature Communications|2022|243
Plastome phylogeny and early diversification of Brassicaceae
|BMC Genomics|2017|211